The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease

Sabita S. Soedamah-Muthu, Val Charlton-Menys, Weihang Bao, Casper Schalkwijk, Coen D. A. Stehouwer, Helen M. Colhoun, D. John Betteridge, Paul N. Durrington, Graham A. Hitman, H. Andrew W. Neil, Shona J. Livingstone, John H. Fuller, David A. DeMicco, Gregory M. Preston

Research output: Contribution to journalArticlepeer-review

Abstract

We examined the effect of atorvastatin (and placebo) on tumour necrosis factor (TNF)a, soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular cell adhesion molecule-1 (sICAM-1) in patients with type 2 diabetes without prior cardiovascular disease (CVD) and investigated whether adhesion molecules were associated with incident CVD. Baseline and follow-up concentrations of TNFa, sVCAM-1 and sICAM-1 were measured in patients from the Collaborative AtoRvastatin Diabetes Study (CARDS). Patients had a mean age of 61 years (standard deviation = 8) and 70% were men. TNFa 2.20 pg/mL (1.82-2.86), sVCAM-1 865 ng/mL (729-1059) and sICAM-1 619 ng/mL (533-753) concentrations (median, interquartile range 25, 75%) were similar at baseline in atorvastatin (given values) and placebo groups and not significantly different at 2 years. The multivariable hazard ratios for the associations between sVCAM-1 and sICAM-1 (doubling the concentration) and CVD were, 0.82 (95% confidence interval (CI) 0.66-1.0) and 0.59 (95% CI 0.50-0.71), respectively. In conclusion atorvastatin had no significant effect on TNFa, sVCAM-1 or sICAM-1 levels in type 2 diabetic patients without a prior history of CVD compared with placebo. In addition, both sVCAM-1 and sICAM-1 concentrations were associated with a decreased risk of CVD. © SAGE Publications 2011.
Original languageEnglish
Pages (from-to)288-297
Number of pages10
JournalBritish Journal of Diabetes and Vascular Disease
Volume11
Issue number6
DOIs
Publication statusPublished - 2011

Fingerprint

Dive into the research topics of 'The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease'. Together they form a unique fingerprint.

Cite this